HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Survodutide spurred weight loss Wall Street analysts referred to as “Wegovy-like,” and showed signs it might help preserve muscle mass as well.

By BioPharma Dive · Apr 28, 2026 · via BioPharma Dive
Boehringer dual-acting obesity shot hits mark in Phase 3 trial

Image: BioPharma Dive

This is an aggregated industry headline. Read the full story at BioPharma Dive →

Tags
pipelineformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
PipelineFierceBiotech ↗
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
May 2, 2026
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
PipelineBriefing
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
May 2, 2026
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
PipelineBioPharma Dive ↗
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
May 1, 2026